

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/378867468>

Balancing Act: Deciphering the Significance of CD4/CD8 Ratios in HIV Immunology

Article · March 2024

DOI: 10.58538/IJIAR/2080

CITATIONS

0

READS

3

5 authors, including:



Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)

1,422 PUBLICATIONS 11,224 CITATIONS

SEE PROFILE



Getrude Uzoma Obeagu
Kampala International University (KIU)

384 PUBLICATIONS 3,307 CITATIONS

SEE PROFILE



Journal home page: <http://www.journalijar.com>

INTERNATIONAL JOURNAL
OF INNOVATIVE AND APPLIED RESEARCH

RESEARCH ARTICLE

Article DOI:10.58538/IJAR/2080

DOI URL: <http://dx.doi.org/10.58538/IJAR/2080>

Balancing Act: Deciphering the Significance of CD4/CD8 Ratios in HIV Immunology

Emmanuel Ifeanyi Obeagu¹, Chioma Ibe², Getrude Uzoma Obeagu³, Chinyere Nkemjika Anyanwu⁴ and Ebere Emilia Ayogu^{5,6}

¹Department of Medical Laboratory Science, Kampala International University, Ishaka, Uganda.

²Department of Nursing Science, Faculty of Health Sciences, Imo State University, Owerri.

³School of Nursing Science, Kampala International University, Ishaka, Uganda.

⁴Department of Microbiology and Immunology, Kampala International University, Western Campus, Uganda.

⁵Department of Clinical Pharmacy and Pharmacy, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Enugu State, Nigeria.

⁶Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy, Kampala International University, Western Campus, Uganda.

Manuscript Info

Manuscript History

Received: 21 January 2024

Final Accepted: 25 February 2024

Published: February 2024

Keywords:

HIV, CD4/CD8 ratio, immune response, disease progression, antiretroviral therapy, immunological markers

Abstract

The management of Human Immunodeficiency Virus (HIV) necessitates a nuanced comprehension of immune responses, with the CD4/CD8 ratio emerging as a pivotal parameter in this regard. This review investigates the clinical implications of CD4/CD8 ratios in HIV, encompassing their role as prognostic markers, treatment monitoring tools, and indicators of immunological reconstitution during antiretroviral therapy. We explore the baseline CD4/CD8 ratio in healthy individuals, scrutinize its prognostic significance in HIV progression, and assess its dynamic changes throughout treatment. Additionally, the article addresses challenges, controversies, and future directions in CD4/CD8 ratio research, offering a comprehensive overview of its potential as a key immunological marker in the ongoing battle against HIV.

*Corresponding Author:- Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

Introduction:-

Human Immunodeficiency Virus (HIV) remains one of the most formidable challenges to global public health, necessitating a continuous quest for deeper insights into the intricacies of immune responses. At the heart of this exploration lies the CD4/CD8 ratio, a critical immunological parameter that holds promise as a key determinant of disease progression, treatment efficacy, and overall prognosis in individuals infected with HIV. As our understanding of the virus has evolved, so too has the recognition of the CD4/CD8 ratio as a delicate balance that shapes the course of the disease.¹⁻⁹ The immune system's ability to maintain equilibrium between CD4 and CD8 T-cell populations is fundamental to its function. In healthy individuals, this delicate balance ensures a robust defense against pathogens. However, in the context of HIV infection, this equilibrium is disrupted, leading to profound implications for the immune response. This introduction aims to unravel the foundations of HIV immunology, emphasizing the pivotal role of the CD4/CD8 ratio as a central player in the dynamic interplay between the virus and the host immune system.¹⁰⁻²⁰

Beyond its role in health and disease, the CD4/CD8 ratio serves as a window into the progression of HIV. Alterations in this ratio have been proposed as early indicators of disease severity and mortality, making it a potential prognostic marker of paramount importance. By examining the normal range and variations in CD4/CD8 ratios in healthy individuals, we can establish a baseline for understanding the deviations observed in HIV-infected patients and discern the clinical significance of these variations.²¹⁻³¹ As the cornerstone of HIV management, antiretroviral therapy (ART) has transformed the landscape of the disease. Monitoring treatment efficacy, however, remains a complex challenge. The CD4/CD8 ratio emerges as a valuable tool in this context, reflecting the immunological response to therapy and offering insights into the overall well-being of the patient. This introduction explores the potential of CD4/CD8 ratios as treatment monitoring markers, shedding light on their dynamic changes throughout the course of therapy.³²⁻³⁶ Immunological reconstitution, a hallmark of successful ART, further underscores the relevance of CD4/CD8 ratios. The restoration of immune function is a critical aspect of long-term HIV care, and understanding the role of CD4/CD8 ratios in this process provides valuable insights into the quality of immune reconstitution and its impact on clinical outcomes. This introduction sets the stage for a comprehensive exploration of the interplay between CD4/CD8 ratios and immunological reconstitution during the course of HIV treatment.³⁷⁻⁴⁶

CD4/CD8 Ratio in Healthy Individuals

The CD4/CD8 ratio, a fundamental parameter reflecting the balance between T-cell subsets, plays a crucial role in maintaining immune homeostasis in healthy individuals. In healthy individuals, the CD4/CD8 ratio is typically characterized by a harmonious balance between helper T cells (CD4+) and cytotoxic T cells (CD8+). This equilibrium is essential for orchestrating effective immune responses against a wide array of pathogens. The CD4+ T cells contribute to the coordination of immune responses by facilitating antibody production and activating other immune cells, while CD8+ T cells are pivotal in the direct elimination of infected cells. The delicate interplay between these two subsets ensures a robust and adaptive immune system. Variations in the CD4/CD8 ratio among healthy individuals are influenced by factors such as age, genetics, and environmental exposures. It is crucial to recognize that a

dynamic range exists within the normal CD4/CD8 ratio, reflecting the diversity of immune responses in different individuals. These variations, while within a relatively stable range, underscore the complexity of immune regulation and highlight the need for personalized benchmarks when assessing immunological health.⁴⁷⁻⁵⁷

The CD4/CD8 ratio serves not only as a marker of immune competence but also as an indicator of overall health. Deviations from the established range may be associated with underlying conditions or immune dysregulation. An abnormally low CD4/CD8 ratio, for instance, may suggest compromised immune function, potentially predisposing an individual to increased susceptibility to infections and other immune-related disorders. Furthermore, the CD4/CD8 ratio in healthy individuals may exhibit fluctuations in response to various physiological stimuli, such as stress, exercise, and vaccination. These transient changes underscore the dynamic nature of the immune system and the adaptability required to maintain equilibrium in the face of external challenges.⁵⁸⁻⁶⁸

CD4/CD8 Ratio as a Prognostic Marker

The CD4/CD8 ratio, a critical immunological parameter, has emerged as a promising prognostic marker in the context of Human Immunodeficiency Virus (HIV) infection. This ratio, reflecting the balance between helper T cells (CD4+) and cytotoxic T cells (CD8+), offers valuable insights into disease progression and serves as a key determinant of clinical outcomes for individuals living with HIV. In individuals with well-controlled HIV, a higher CD4/CD8 ratio is associated with better immune function and a lower risk of clinical events. Conversely, a declining or persistently low CD4/CD8 ratio may signal an increased likelihood of immunological decline, heightened susceptibility to opportunistic infections, and a poorer prognosis. One of the primary prognostic implications of the CD4/CD8 ratio lies in its ability to stratify risk among HIV-infected individuals. A lower baseline CD4/CD8 ratio has been linked to a higher risk of morbidity and mortality, providing clinicians with a valuable tool for risk assessment and tailored patient management. Moreover, the CD4/CD8 ratio demonstrates prognostic utility not only in untreated HIV but also during antiretroviral therapy (ART), where its dynamics offer insights into treatment response and long-term outcomes. Beyond its prognostic value in predicting clinical events, the CD4/CD8 ratio has demonstrated significance in forecasting non-AIDS-related complications, such as cardiovascular disease and neurocognitive decline. This multifaceted prognostic capability underscores the comprehensive impact of the CD4/CD8 ratio on overall health and well-being in the context of HIV. The predictive power of the CD4/CD8 ratio extends to its utility in identifying individuals at risk of immune non-response despite viral suppression. Even in cases where ART successfully controls viral replication, a persistently low CD4/CD8 ratio may indicate suboptimal immune recovery, necessitating closer monitoring and potential therapeutic interventions.⁶⁹⁻⁻⁸⁶

Implications for Treatment Monitoring

The CD4/CD8 ratio, a dynamic reflection of immune balance, holds profound implications for the monitoring of Human Immunodeficiency Virus (HIV) treatment. As antiretroviral therapy (ART) remains the cornerstone of HIV management, understanding the nuanced interplay between CD4+ and CD8+ T-cell subsets provides crucial insights into treatment efficacy,

immune reconstitution, and overall patient well-being. Monitoring the CD4/CD8 ratio serves as a valuable tool for evaluating the effectiveness of antiretroviral therapy. A rising CD4/CD8 ratio often signifies positive treatment response, indicating immune recovery and a reduction in the risk of opportunistic infections. Conversely, a stagnant or declining ratio may prompt clinicians to reassess the treatment regimen, considering potential virologic failure or suboptimal immune reconstitution. The process of immunological reconstitution, a key goal of ART, involves rebuilding the immune system's capacity to respond to infections. The CD4/CD8 ratio provides a nuanced perspective on this reconstitution, helping clinicians gauge the quality of immune recovery. A normalized or improving CD4/CD8 ratio indicates favorable immunological reconstitution, while a persistent imbalance may signal challenges in achieving optimal immune restoration.⁸⁷⁻⁸⁹

Despite viral suppression achieved through ART, some individuals may experience suboptimal immune recovery, termed immune non-response. Monitoring the CD4/CD8 ratio assists in identifying such cases, allowing for timely intervention and potentially guiding adjustments to the treatment plan. This proactive approach is essential in preventing long-term complications and optimizing the overall health of HIV-infected individuals. The CD4/CD8 ratio continues to serve as a prognostic marker even during ART, aiding in risk stratification for opportunistic infections. Individuals with persistently low CD4/CD8 ratios may remain at an elevated risk, necessitating vigilant monitoring and preventive measures to mitigate the potential impact of opportunistic infections on the course of HIV. Tailoring HIV management to individual patient needs is a key objective. Monitoring the CD4/CD8 ratio contributes to the development of personalized treatment strategies. Clinicians can use this ratio to guide decisions on treatment intensity, frequency of monitoring, and potential modifications to the antiretroviral regimen, ensuring a targeted and patient-centered approach to care. The CD4/CD8 ratio's role in treatment monitoring extends beyond immediate clinical outcomes. Long-term health implications, including the risk of non-AIDS-related complications, cardiovascular disease, and neurocognitive decline, can be assessed through the ongoing observation of CD4/CD8 dynamics.⁹⁰

Immunological Reconstitution and CD4/CD8 Ratios

Immunological reconstitution, a hallmark of successful antiretroviral therapy (ART) in Human Immunodeficiency Virus (HIV) management, is a multifaceted process that involves rebuilding the immune system's capacity to respond effectively to pathogens. Central to this intricate journey is the CD4/CD8 ratio, a dynamic immunological parameter that offers crucial insights into the quality and resilience of immune reconstitution in individuals living with HIV. Immunological reconstitution in the context of HIV refers to the restoration of CD4+ T-cell counts, essential for orchestrating immune responses. ART aims to suppress viral replication, allowing the immune system to recover and rebuild its protective capabilities. The CD4/CD8 ratio becomes a key metric in gauging the success of this reconstitution, offering a comprehensive view of immune balance restoration. Initiation of ART triggers a series of immunological changes, and the CD4/CD8 ratio undergoes significant fluctuations during the early stages of treatment. An initial rise in CD4+ T-cell counts, coupled with a decline in CD8+ T-cell counts, contributes to the early improvement in the CD4/CD8 ratio. Monitoring these

dynamics aids in assessing the initial response to therapy and provides a glimpse into the trajectory of immunological reconstitution.⁹¹

A normalized or improving CD4/CD8 ratio signifies favorable immunological reconstitution, reflecting the restoration of immune function and resilience. This ratio serves as a valuable marker of immunological health, indicating the ability of the immune system to mount appropriate responses to infections and maintain equilibrium between T-cell subsets. Despite viral suppression, some individuals may experience persistent imbalances in the CD4/CD8 ratio, indicating challenges in achieving optimal immune reconstitution. Persistent low ratios are associated with an increased risk of opportunistic infections and non-AIDS-related complications, emphasizing the need for vigilant monitoring and potential therapeutic interventions to address underlying immune dysregulation. The CD4/CD8 ratio plays a pivotal role in risk stratification, helping clinicians identify individuals at higher risk of immune non-response. Tailoring interventions based on CD4/CD8 dynamics allows for personalized approaches to enhance immune recovery, potentially involving treatment intensification, immune-modulating therapies, or adjustments to the antiretroviral regimen. While CD4 counts traditionally dominated discussions on immune recovery, the CD4/CD8 ratio provides a more comprehensive view. It considers the balance between CD4+ and CD8+ T cells, acknowledging the intricate interplay between these subsets in maintaining immune equilibrium. This broader perspective contributes to a more nuanced understanding of the quality of immunological reconstitution.⁹⁰

Conclusion

The CD4/CD8 ratio's role as a prognostic marker offers a glimpse into the potential course of HIV, aiding in risk stratification and individualized patient management. Its ability to predict not only AIDS-related complications but also non-AIDS-related comorbidities positions it as a sentinel marker, allowing clinicians to tailor interventions for improved patient outcomes. As our understanding of the CD4/CD8 ratio's prognostic significance deepens, it becomes a cornerstone in the foundation of precision medicine within HIV care. In the realm of treatment monitoring, the CD4/CD8 ratio becomes a dynamic gauge of the efficacy of antiretroviral therapy. Its sensitivity to shifts in treatment response provides real-time insights, guiding clinicians in decision-making processes, and ensuring timely adjustments to optimize therapeutic outcomes. The CD4/CD8 ratio becomes an ally in the pursuit of sustained viral suppression, immune recovery, and the prevention of long-term complications, enhancing the quality of life for those living with HIV.

Immunological reconstitution, a central objective of ART, finds a reliable companion in the CD4/CD8 ratio. This ratio acts as a vigilant observer, reflecting the quality and resilience of immune recovery. Monitoring CD4/CD8 dynamics facilitates the identification of immune non-responders, enabling clinicians to implement targeted interventions and address underlying immune dysregulation, ultimately steering the course towards optimal immunological health.

References

1. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
2. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology*. 2024;2(1):34-46.
3. Waldman AJ, Balskus EP. The human microbiota, infectious disease, and global health: challenges and opportunities. *ACS infectious diseases*. 2018;4(1):14-26.
4. Sannier G, Dubé M, Kaufmann DE. Single-cell technologies applied to HIV-1 research: reaching maturity. *Frontiers in Microbiology*. 2020; 11:509151.
5. Obeagu EI, Obeagu GU, Ukibe NR, Oyebadejo SA. Anemia, iron, and HIV: decoding the interconnected pathways: A review. *Medicine*. 2024;103(2): e36937.
6. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
7. Salido J, Czernikier A, Trifone C, Polo ML, Figueroa MI, Urioste A, Cahn P, Sued O, Salomon H, Laufer N, Ghiglione Y. Pre-cART immune parameters in people living with HIV might help predict CD8+ T-cell characteristics, inflammation levels, and reservoir composition after effective cART. *Pathogens and Immunity*. 2021;6(2):60.
8. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology*. 2024;2(1):1-3.
9. Serrano-Villar S, Vázquez-Castellanos JF, Vallejo A, Latorre A, Sainz T, Ferrando-Martínez S, Rojo D, Martínez-Botas J, del Romero J, Madrid N, Leal M. The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects. *Mucosal immunology*. 2017;10(5):1279-93.
10. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
11. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
12. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
13. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
14. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
15. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38. DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)

16. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci.* 2023;9(2): 1-5. DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
17. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
18. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
19. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-19.
20. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International.* 2020;32(22):101-119.
21. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation.* 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
22. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences.* 2015;4(4):911-916. [https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
23. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65. DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
24. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001)
25. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-119.
26. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanjo CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State, Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-](https://doi.org/10.22192/ijcrms.2023.09.02.001)

[SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](#).

27. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130.[links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](#).
28. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144.https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al_IJCRAR.pdf.
29. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4.[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](#)
30. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](#)
31. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
32. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139.[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](#).
33. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-134.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
34. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022:29-34.
35. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
36. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri.* 2022; 5 (8). 2022;137.[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](#).

37. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142. DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://www.ijarbs.com/links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
38. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134. DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://www.ijarbs.com/links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf)
39. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104. DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014) https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
40. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
41. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences.* 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
42. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183. DOI: [10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://www.jccm.com/links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf)
43. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
44. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
45. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases.* 2022;10(4):1-7.

46. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-368.
47. Sinclair C, Bains I, Yates AJ, Seddon B. Asymmetric thymocyte death underlies the CD4: CD8 T-cell ratio in the adaptive immune system. *Proceedings of the National Academy of Sciences*. 2013;110(31): E2905-2914.
48. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):42-57.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
49. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
50. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023;10(8): 564-568
51. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.
<links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf>.
52. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-49.
53. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-8. DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)
<links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf>.
54. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):6-13. DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002)
<links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf>.
55. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2016;2(4):29-33.<links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf>.
56. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci*. 2015;4(4):906-

- 910.https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
57. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
58. Wikby A, Johansson B, Olsson J, Löfgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. *Experimental gerontology.* 2002;37(2-3):445-543.
59. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS).* 2023;3(2):28-31.
60. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review.* *Newport International Journal of Public Health and Pharmacy (NIJPP).* 2023;3(2):64-67.
61. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS).* 2023;3(2):95-99.
62. Ibebuikie JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research,* 2018; 1 (2):08-14.<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
63. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
64. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.
65. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
66. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
67. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
68. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES).* 2023;3(2):56-59.

69. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
70. Chen J, Liu X, Qin S, Ruan G, Lu A, Zhang J, Wu Y, Xie Z, Peng J. A novel prognostic score including the CD4/CD8 for AIDS-related lymphoma. *Frontiers in Cellular and Infection Microbiology*. 2022; 12:919446.
71. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
72. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
73. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood TransfusDisord*. 2018;1(2).
74. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
75. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
76. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
77. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
78. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
79. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
80. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
81. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep*. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.

82. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
83. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
84. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
85. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
86. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
87. Romero-Martín L, Tarrés-Freixas F, Pedreño-López N, de la Concepción ML, Cunyat F, Blanco J, Brander C, Olvera A. T-follicular-like CD8+ T cell responses in chronic HIV infection are associated with virus control and antibody isotype switching to IgG. *Frontiers in Immunology*. 2022; 13:928039.
88. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health*. 2024;2(1):8-22.
89. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology*. 2024;2(1):14-33.
90. Qin F, Lv Q, Hong W, Wei D, Huang K, Lan K, Chen R, Liu J, Liang B, Liang H, Liang H. Association between CD4/CD8 ratio recovery and chronic kidney disease among human immunodeficiency virus-infected patients receiving antiretroviral therapy: A 17-year observational cohort study. *Frontiers in Microbiology*. 2022; 13:827689.
91. Ta TM, Malik S, Anderson EM, Jones AD, Perchik J, Freylikh M, Sardo L, Klase ZA, Izumi T. Insights into persistent HIV-1 infection and functional cure: novel capabilities and strategies. *Frontiers in Microbiology*. 2022; 13:862270.